At Northwestern Medicine, we put our patients first in an effort to deliver the best cancer care. Our teams of experts are here to help support patients and their caregivers during all stages of their cancer journey: diagnosis, treatment, and recovery.
Northwestern Medicine’s cancer centers provide access to state-of-the art therapies and comprehensive cancer care offering leading-edge medical, surgical and radiation oncology treatment options, as well as access to specialized research, clinical trials and diagnostic services.
Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital is proud to be ranked as one of the top 8 cancer programs in the country by U.S. News & World Report.
Closing Thoughts and Key Takeaways on Small Cell Lung Cancer
August 6th 2024In a forward-looking discussion, Ticiana Leal, MD; Anne Chiang, MD, PhD; Afshin Dowlati, MD; and Tarita O. Thomas, MD, PhD, offer their concluding insights on the evolving landscape of clinical trials and the future directions of small cell lung cancer (SCLC) treatment, highlighting promising areas of research and potential breakthroughs that may shape the management of this challenging disease in the years to come.
Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC
July 30th 2024Medical experts review the Ideate-Lung02 phase 3 clinical trial, exploring the potential for ifinatamab to elicit durable responses in patients with advanced small cell lung cancer (SCLC), and discussing the implications of these findings for the future treatment landscape of SCLC.
DELLphi-301: Platinum Chemotherapy Efficacy in SCLC Survival
July 23rd 2024In a detailed analysis, key opinion leaders (KOLs) review the results of the DELLphi-301 Phase 2 clinical trial, assessing the efficacy of platinum-based chemotherapy in the treatment of small cell lung cancer (SCLC) and its impact on overall survival outcomes for patients enrolled in the study.
Navigating Later-Line Therapy Sequencing in LS-SCLC Progression
July 23rd 2024In a focused discussion, Anne Chiang, MD, PhD, explores the sequencing of later-line therapies for limited-stage small cell lung cancer (LS-SCLC), emphasizing key factors to consider when making treatment decisions for patients who have progressed on initial therapy.